Exciting news from Amgen as Uplizna proves its worth in another rare disease setting! Learn more about the regulatory filings in the US and EU. #RareDisease #Amgen #Uplizna
Sage Addie’s Post
More Relevant Posts
-
Exciting news from Amgen as Uplizna proves its worth in another rare disease setting! Learn more about the regulatory filings in the US and EU. #RareDisease #Amgen #Uplizna
Amgen's Uplizna proves its worth in another rare disease, setting up regulatory filings in US and beyond
fiercepharma.com
-
Exciting news from Amgen as Uplizna proves its worth in another rare disease setting! Learn more about the regulatory filings in the US and EU. #RareDisease #Amgen #Uplizna
Amgen's Uplizna proves its worth in another rare disease, setting up regulatory filings in US and beyond
fiercepharma.com
-
Exciting news from Amgen as Uplizna proves its worth in another rare disease setting! Learn more about the regulatory filings in the US and EU. #RareDisease #Amgen #Uplizna
Amgen's Uplizna proves its worth in another rare disease, setting up regulatory filings in US and beyond
fiercepharma.com
-
Exciting news from Amgen as Uplizna proves its worth in another rare disease setting! Learn more about the regulatory filings in the US and EU. #RareDisease #Amgen #Uplizna
Amgen's Uplizna proves its worth in another rare disease, setting up regulatory filings in US and beyond
fiercepharma.com
-
Exciting news from Amgen as Uplizna proves its worth in another rare disease setting! Learn more about the regulatory filings in the US and EU. #RareDisease #Amgen #Uplizna
Amgen's Uplizna proves its worth in another rare disease, setting up regulatory filings in US and beyond
fiercepharma.com
-
Insmed Incorporated stocks soar as Phase III lung disease drug exceeds expectations: If Insmed’s brensocatib is given the green light, it would be the first therapy approved for patients with bronchiectasis. The highly anticipated ASPEN trial (NCT04594369) was a global, randomised, double-blind, placebo-controlled Phase III study to assess the efficacy, safety, and tolerability of #brensocatib in patients with non-cystic fibrosis bronchiectasis. https://lnkd.in/gBKXBXBi #Regulatorycompliance #RegulatoryStrategy
Insmed stocks soar as Phase III lung disease drug exceeds expectations
clinicaltrialsarena.com
-
Partner Content - PCM TRIALS - Quality Mobile Research explains why mobile visits are critical for the decentralization of rare disease research As rare disease drug development gains momentum, the growing movement towards decentralized clinical trials could not be more well-timed. In this article, we discuss the important synergy between the two trends and look at data around the increasing use of mobile visits in rare disease protocols. - https://lnkd.in/d3Jqugg7 #dct #decentralizedclinicaltrials #digitaltrials #decentralizedtrials #clinicaltrials #raredisease
Mobile visits are critical for the decentralization of rare disease research
clinicaltrialsarena.com
-
For decades, steroids have been considered a necessary evil to control ANCA-associated vasculitis. Yet today, more patients die from complications associated with glucocorticoid treatment than the underlying disease. Get a summary of the most comprehensive picture to date of evolving diagnostic and therapeutic strategies for this rare but devastating #AutoimmuneDisorder: https://hubs.li/Q02rhSdw0 #Vasculitis #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicity #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications
Steroid-toxicity and ANCA-associated Vasculitis: How Far Have We Come in 40 Years?
steritas.com
-
Excited to share that I'll be presenting at the 7th Antigen Specific Immune Tolerance Summit in Boston! Looking forward to exchanging insights and exploring advancements in immune tolerance.🌐🔬 Happy to share some of the data we're preparing for the meeting, feel free to reach out with any questions. #Immunetolerance #ASIT #Immunology
We're pleased to announce our upcoming presentation at the 7th Antigen-Specific Immune Tolerance Drug Development Summit. 🔍 The Landscape of Auto-Antigen-Specific Immune Tolerance Therapies for Autoimmune Diseases 🗓️ Date: March 19th 🕒 Time: 9:30am Our expert Account Lead, Luka Vukoje, will be Reviewing the landscape of auto-antigen-specific immune tolerance therapies, as well as delving into what the field can expect for the road ahead, to address the landscape head-on. Access the full presentation details here 👉 https://lnkd.in/eZ28a7ui Luka will also be on hand to discuss any of the data presented, the autoimmune diseases landscape, and how our Beacon Immune Tolerance solution can support you with your drug development pipelines. Head to the booth and grab some goodies too! #ASIT2024 #ASIT #antigen #antigenspecific #autoimmune #autoimmunediseases #immunetolerance
-
-
For decades, steroids have been considered a necessary evil to control ANCA-associated vasculitis. Yet today, more patients die from complications associated with glucocorticoid treatment than the underlying disease. Get a summary of the most comprehensive picture to date of evolving diagnostic and therapeutic strategies for this rare but devastating #AutoimmuneDisorder: https://hubs.li/Q02qxYW20 #Vasculitis #AutoimmuneDiseaseManagement #SteritasGTI #SteroidToxicity #SteroidToxicityAwareness #VasculitisTreatment #SteroidInducedComplications
Steroid-toxicity and ANCA-associated Vasculitis: How Far Have We Come in 40 Years?
steritas.com
